Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc.
Case Number:
13-1338
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
July 01, 2014
Fed. Circ. Upholds Ruling Nixing AbbVie Antibody Patents
The Federal Circuit on Tuesday affirmed a lower court's ruling that two antibody patents that AbbVie Inc. accused Johnson & Johnson unit Janssen Biotech Inc.'s psoriasis treatment Stelara of infringing are invalid for lacking an adequate written description.
-
March 06, 2014
AbbVie Pushes Fed. Circ. To Resurrect Antibody Patent Spat
AbbVie Deutschland GmbH & Co. urged a Federal Circuit panel on Thursday to resurrect two of its antibody patents, alleging that "presumptively prejudicial" jury instructions doomed its infringement suit against a Johnson & Johnson subsidiary.